secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001437749-24-034551
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q3 2024 revenue jumps to $1.96M; net loss narrows to $0.20M
------------------------------------------------------------------

- Revenue of ~$1.958M vs $397K in Q3 2023, driven by $1M Proliant milestone and $425K Inzyme success fee.
- Net loss of $203K vs $1.614M a year ago; operating loss fell to $203K from $1.720M.
- Cash & investment-grade securities at $10.0M as of Sep 30, 2024, up from $7.3M at Dec 31, 2023.
- Received $1M milestone from Proliant for animal-free recombinant albumin; first product launch expected H1 2025.
- Advanced C1-produced Mpox antigen with ViroVax (4.5 g/L in 7 days); preclinical studies start Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924034551/0001437749-24-034551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924034551/dyai20240905_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer